Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06309225 · ClinicalTrials.gov registry record · NA

Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly

A NA study of Frailty and Oropharynx Cancer, sponsored by Omar Mahmoud.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06309225: Recruiting NA study of Frailty and Oropharynx Cancer, sponsored by Omar Mahmoud.

NCT06309225 is a NA study of Frailty and Oropharynx Cancer that is actively recruiting participants, run by Omar Mahmoud. The registered enrollment target is 20 participants, below the 1,506-participant average among 48 other Frailty trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06309225, a NA study of Frailty and Oropharynx Cancer, is actively recruiting participants, sponsored by Omar Mahmoud.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy. Recently, investigators have noticed similar high rates of cancer control in small numbers of patients who receive less intensive treatments using lower doses of radiation, smaller radiation fields with chemotherapy. It is expected that the side effects of treatment with lower doses of radiation would be less. For this reason this study is looking at a different regimen of reducing the intensity of the treatment. The purpose of this study is to compare any good and bad effects of using lower dose smaller fields radiation therapy and chemotherapy with published outcomes. This study will allow the researchers to know whether these different approaches are better, the same, or worse than the usual approach. To be better, the study approach should result in the same survival rate of the usual approach (about 85 out of 100 patients alive and free of cancer at 2 years) but with less long-term side effects.

Primary Outcome

Assuming the primary endpoint (non-inferior 2 year locoregional control) is met and both of these toxicity outcome goals are met, then concurrent short course radiotherapy would be considered an effective and less toxic alternative to concurrent standard arm, in locally advanced HPV-associated carcinoma of the oropharynx.

Interventions

  • RADIATION Modified dose and fields intensity modulated radiotherapy

Study Locations (1)

Florida

  • Baptist MD Anderson Cancer Center - Jacksonville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-05-15
Est. Completion 2026-09-30
Phase NA
Omar Mahmoud

1 total trials

What NCT06309225 shows while recruiting

NCT06309225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,506-participant average among 48 other Frailty trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Frailty appearing as the primary indexed condition, and to 1 intervention - of which Modified dose and fields intensity modulated radiotherapy is the first listed.

NCT06309225 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06309225 about?

NCT06309225 is a clinical study titled "Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly". Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy. Recently, investigators have noticed similar high rates of cancer control in small numbers of pati...

What is the current status of trial NCT06309225?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-05-15. Estimated completion is 2026-09-30.

What conditions does trial NCT06309225 study?

This clinical trial studies the following conditions: Frailty, Oropharynx Cancer.

What interventions are being tested in trial NCT06309225?

The interventions under investigation include: Modified dose and fields intensity modulated radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT06309225?

This trial is sponsored by Omar Mahmoud, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06309225 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Frailty

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06309225's enrollment target sits among peer trials

20 42nd of 48 higher than 6 of 48 other Frailty trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Frailty trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06309225, the US trial registry maintained by the National Library of Medicine. NCT06309225 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.